[en] [en] OBJECTIVE: To evaluate outcomes of European cross-border multidisciplinary tumor boards in terms of participation, adherence to treatment recommendations, and access to novel treatment strategies.
METHODS: The European reference network for rare gynecological tumors (EURACAN G2 domain) aims to improve the diagnosis, management, and treatment of patients with these cancers. Cross-border multidisciplinary tumor boards were initiated to facilitate intercollegiate clinical discussions across Europe and increase patients' access to specialist treatment recommendations and clinical trials. All G2 healthcare providers were invited to participate in monthly multidisciplinary meetings. Patient data were collected using a standardized form and case summaries were distributed before each meeting. After each tumor board, a meeting summary with treatment recommendations was sent to all participants and the project manager at the coordinating center. The multidisciplinary tumor board format and outcomes were regularly discussed at G2 domain meetings. Anonymized clinical data and treatment recommendations were registered in a prospective database. For this report, clinical data were collected between November 2017 and December 2020 and follow-up data retrieved until May 2021.
RESULTS: During the 3-year period, 31 multidisciplinary tumor boards were held with participants from 10 countries and 20 centers. 91 individual patients were discussed between one and six times for a total of 109 case discussions. Follow-up data were retrieved from 64 patients and 80 case discussions. Adherence to treatment recommendations was 99%. Multidisciplinary tumor board recommendations resulted in 11 patients getting access to off-label treatment and one patient being enrolled in a clinical trial in another European country. 14/91 patients were recommended for surveillance only when additional treatment had been considered locally.
CONCLUSION: Cross-border multidisciplinary tumor boards enable networking and clinical collaboration between healthcare professionals in different countries. Surveillance strategies, off-label drug use, and increased participation in clinical trials are possible benefits to patients with rare gynecological tumors.
Disciplines :
Oncology
Author, co-author :
Joneborg, Ulrika ; Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden ulrika.joneborg@regionstockholm.se ; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
Bergamini, Alice; San Raffaele Hospital Department of Obstetrics and Gynaecology, Milano, Italy ; Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milano, Italy
Wallin, Emelie; Department of Pelvic Cancer, Karolinska University Hospital, Stockholm, Sweden ; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
Mangili, Giorgia; San Raffaele Hospital Department of Obstetrics and Gynaecology, Milano, Italy
Solheim, Olesya ; Department of Gynecological Oncology, Oslo University Hospital, Oslo, Norway
Marquina, Gloria ; Department of Medical Oncology, Hospital Clinico San Carlos, Madrid, Spain ; Department of Medicine, Complutense University of Madrid, Madrid, Spain
Casado, Antonio; Department of Medicine, Complutense University of Madrid, Madrid, Spain ; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain
Rokkones, Erik; Department of Gynecological Oncology, Oslo University Hospital, Oslo, Norway
Coulter, John; Department of Gynaecological Oncology, Cork University Hospital, Cork, Ireland
Lok, Christianne A R ; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
van Trommel, Nienke; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Amant, Frédéric ; Division of Gynecologic Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium ; Division of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands
Bolze, Pierre-Adrien; Hospices Civils de Lyon, Universite Lyon 1 Faculte de Medecine et de Maieutique Lyon-Sud Charles Merieux, Lyon, France ; Department of Gynecological and Oncological Surgery and Obstetrics, Hospital Lyon-South, Lyon, France
Sehouli, Jalid ; Department of Gynecology with Center of Oncological Surgery, Charite Medical Faculty Berlin, Berlin, Germany
Han, Sileny ; Division of Gynecologic Oncology, KU Leuven University Hospitals Leuven, Leuven, Belgium
Kridelka, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR)
Pautier, Patricia; Gustave Roussy Institute, Villejuif, France ; Paris-Saclay University, Villejuif, France
Ray-Coquard, Isabelle ; Centre Leon Berard, Lyon, France ; Université Claude Bernard Lyon 1, Villeurbanne, France
Seckl, Michael ; Department of Medical Oncology, Imperial College London - Charing Cross Campus, London, UK
Blay J-Y, Casali P, Bouvier C, et al. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open 2021; 6: 100174. doi:10.1016/j.esmoop.2021.100174
Gatta G, van der Zwan JM, Casali PG, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-511. doi:10.1016/j.ejca.2011.08.008
Chiannilkulchai N, Pautier P, Genestie C, et al. Networking for ovarian rare tumors: a significant breakthrough improving disease management. Ann Oncol 2017; 28: 1274-9. doi:10.1093/annonc/mdx099
Ray-Coquard I, Trama A, Seckl MJ, et al. Rare ovarian tumours: epidemiology, treatment challenges in and outside a network setting. Eur J Surg Oncol 2019; 45: 67-74. doi:10.1016/j.ejso.2017.09.025
Gatta G, Capocaccia R, Botta L, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 2017; 18: 1022-39. doi:10.1016/S1470-2045(17)30445-X
Gatta G, Trama A, Capocaccia R, et al. Epidemiology of rare cancers and inequalities in oncologic outcomes. Eur J Surg Oncol 2019; 45: 3-11. doi:10.1016/j.ejso.2017.08.018
Frezza AM, Trama A, Blay J-Y, et al. Networking in rare cancers: what was done, what's next. Eur J Surg Oncol 2019; 45: 16-8. doi:10.1016/j.ejso.2018.03.030
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377: 62-70. doi:10.1056/NEJMra1510062
Blay J-Y, Coindre J-M, Ducimetière F, et al. The value of research collaborations and consortia in rare cancers. Lancet Oncol 2016; 17: e62-9. doi:10.1016/S1470-2045(15)00388-5
Lainé A, Hanvic B, Ray-Coquard I. Importance of guidelines and networking for the management of rare gynecological cancers. Curr Opin Oncol 2021; 33: 442-6. doi:10.1097/CCO.0000000000000760
Leary AF, Quinn M, Fujiwara K, et al. Fifth ovarian cancer consensus conference of the Gynecologic Cancer Intergroup (GCIG): clinical trial design for rare ovarian tumours. Ann Oncol 2017; 28: 718-26. doi:10.1093/annonc/mdw662
Quesada S, Bini M, Lebreton C, et al. Update on new treatments for rare ovarian tumours. Curr Opin Obstet Gynecol 2023; 35: 27-33. doi:10.1097/GCO.0000000000000836
Héon-Klin V. European reference networks for rare diseases: what is the conceptual framework Orphanet J Rare Dis 2017; 12: 137. doi:10.1186/s13023-017-0676-3
Greer HO, Frederick PJ, Falls NM, et al. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. Int J Gynecol Cancer 2010; 20: 1321-5. doi:10.1111/IGC.0b013e3181f5871e
Specchia ML, Frisicale EM, Carini E, et al. The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 2020; 20: 73. doi:10.1186/s12913-020-4930-3
Jackson SE, Chester JD. Personalised cancer medicine. Int J Cancer 2015; 137: 262-6. doi:10.1002/ijc.28940
Saeed RF, Awan UA, Saeed S, et al. Targeted therapy and personalized medicine. Cancer Treat Res 2023; 185: 177-205. doi:10.1007/978-3-031-27156-4_10
Gambardella V, Tarazona N, Cejalvo JM, et al. Personalized medicine: recent progress in cancer therapy. Cancers (Basel) 2020; 12: 1009. doi:10.3390/cancers12041009
Evangelista T, Hedley V, Atalaia A, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European reference networks. Orphanet J Rare Dis 2016; 11: 17. doi:10.1186/s13023-016-0398-y
Sandrucci S, Naredi P, Bonvalot S. Centers of excellence or excellence networks: the surgical challenge and quality issues in rare cancers. Eur J Surg Oncol 2019; 45: 19-21. doi:10.1016/j.ejso.2017.12.012
Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treat Rev 2016; 42: 56-72. doi:10.1016/j.ctrv.2015.11.007
Lee B, Kim K, Choi JY, et al. Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: a prospective study. Medicine (Baltimore) 2017; 96: e8089. doi:10.1097/MD.0000000000008089
Hollunder S, Herrlinger U, Zipfel M, et al. Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer 2018; 18: 936. doi:10.1186/s12885-018-4841-4
Alkasbi J, Mortuaire G, Rysman B, et al. Match between therapeutic proposal in multidisciplinary tumor board and actual treatment in head and neck cancer. Eur Ann Otorhinolaryngol Head Neck Dis 2021; 138: 247-52. doi:10.1016/j.anorl.2020.11.008
Ichikawa M, Uematsu K, Yano N, et al. Implementation rate and effects of multidisciplinary team meetings on decision making about radiotherapy: an observational study at a single Japanese institution. BMC Med Inform Decis Mak 2022; 22: 111. doi:10.1186/s12911-022-01849-y
McBain RK, Sousa JL, Rose AJ, et al. Impact of project ECHO models of medical tele-education: a systematic review. J Gen Intern Med 2019; 34: 2842-57. doi:10.1007/s11606-019-05291-1
Kirch DG, Petelle K. Addressing the physician shortage: the peril of ignoring demography. JAMA 2017; 317: 1947-8. doi:10.1001/jama.2017.2714
White EK, Wagner IV, van Beuzekom C, et al. A critical evaluation of the EU-virtual consultation platform (CPMS) within the European reference network on rare endocrine conditions. Endocr Connect 2022; 11: 11. doi:10.1530/EC-22-0281
Mönig I, Steenvoorden D, de Graaf JP, et al. CPMS-improving patient care in Europe via virtual case discussions. Endocrine 2021; 71: 549-54. doi:10.1007/s12020-021-02628-x
Davis CH, Ho J, Stephenson R, et al. Virtual tumor board increases provider attendance and case presentations. JCO Oncol Pract 2022; 18: e1603-10. doi:10.1200/OP.22.00158
El Saghir NS, Keating NL, Carlson RW, et al. Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book 2014: e461-6. doi:10.14694/EdBook_AM.2014.34.e461
Arora S, Geppert CMA, Kalishman S, et al. Academic health center management of chronic diseases through knowledge networks: project ECHO. Acad Med 2007; 82: 154-60. doi:10.1097/ACM.0b013e31802d8f68
